Pharmaceuticals, Biotechnology and Life Sciences
Royalty Pharma has acquired a partial royalty interest on Prevymis™[1] (letermovir) from AiCuris for a one-time-payment of $220 million.
In the absence of ‘in person’ meetings, access to deep dive pharma insights are not on hold, and later this month experts will discuss how AI is rapidly evolving supply chain dynamics in a ground-breaking Pharmapack Europe webinar (June 17, 2020).
Mylan and Lupin Limited have received from the European Commission (EC) marketing authorization for Nepexto, a biosimilar to Enbrel, for all indications of the reference product.
Mereo BioPharma on Thursday announced the completion of a $70 million (£56 million) private placement (the “Fundraising”) with a number of new and existing U.S based institutional and accredited investors.
FDA published on Wednesday a new batch of product-specific guidances (PSGs), providing recommendations for developing generic drugs and generating the evidence needed to support Abbreviated New Drug Application (ANDA) approval.
The Larvol Group on Monday announced the launch of Veri, their new decision support and competitive intelligence tool during the 2020 ASCO Annual Meeting.
Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is further strengthening its oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for biotechs, pharmaceutical companies and academics.
The FDA is working to address the coronavirus disease (COVID-19) outbreak and keep you and your family informed on the latest developments. Here are answers to some frequently asked questions from consumers about testing:
Italian-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, is preparing to open its Technology Excellence Center in Boston (US TEC), Massachusetts.
On 16 June, Lonza will host a free 60-minute webinar on the latest regulatory developments surrounding the use of the recombinant Factor C (rFC) assay for endotoxin detection in parenteral pharmaceuticals and implantable medical devices.